Roberto Eleopra

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5284525/publications.pdf

Version: 2024-02-01

76196 98622 5,579 142 40 67 citations h-index g-index papers 156 156 156 6476 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology. Pharmacological Reviews, 2017, 69, 200-235.	7.1	506
2	Randomized trial of safinamide addâ€on to levodopa in Parkinson's disease with motor fluctuations. Movement Disorders, 2014, 29, 229-237.	2.2	239
3	Twoâ€year, randomized, controlled study of safinamide as addâ€on to levodopa in mid to late Parkinson's disease. Movement Disorders, 2014, 29, 1273-1280.	2.2	200
4	Different time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E in humans. Neuroscience Letters, 1998, 256, 135-138.	1.0	184
5	Stroke Severity Is a Crucial Predictor of Outcome: An International Prospective Validation Study. Journal of the American Heart Association, 2016, 5, .	1.6	152
6	Effects of <scp>COVID</scp> â€19 on Parkinson's Disease Clinical Features: A <scp>Communityâ€Based Caseâ€Control</scp> Study. Movement Disorders, 2020, 35, 1287-1292.	2.2	148
7	Botulinum neurotoxin serotype C: a novel effective botulinum toxin therapy in human. Neuroscience Letters, 1997, 224, 91-94.	1.0	132
8	The variability in the clinical effect induced by botulinum toxin type A: The role of muscle activity in humans. Movement Disorders, 1997, 12, 89-94.	2.2	113
9	Diagnostic criteria for small fibre neuropathy in clinical practice and research. Brain, 2019, 142, 3728-3736.	3.7	111
10	Different types of botulinum toxin in humans. Movement Disorders, 2004, 19, S53-S59.	2.2	109
11	Motor neuron disease in the province of Ferrara, Italy, in 1964–1982. Neurology, 1988, 38, 1604-1604.	1.5	107
12	Efficient RT-QuIC seeding activity for α-synuclein in olfactory mucosa samples of patients with Parkinson's disease and multiple system atrophy. Translational Neurodegeneration, 2019, 8, 24.	3.6	106
13	Surgery of Insular Nonenhancing Gliomas. Neurosurgery, 2012, 70, 1081-1094.	0.6	97
14	A new potential biomarker for dementia with Lewy bodies. Neurology, 2017, 89, 318-326.	1.5	92
15	Botulism-like syndrome after botulinum toxin type A injections for focal hyperhidrosis. British Journal of Dermatology, 2002, 147, 808-809.	1.4	88
16	Botulinum toxin treatment in the facial muscles of humans. Neurology, 1996, 46, 1158-1160.	1.5	85
17	Explosive-aggressive behavior related to bilateral subthalamic stimulation. Parkinsonism and Related Disorders, 2004, 10, 247-251.	1.1	83
18	<scp><i>GBA</i>â€Related</scp> Parkinson's Disease: Dissection of Genotype–Phenotype Correlates in a Large Italian Cohort. Movement Disorders, 2020, 35, 2106-2111.	2.2	83

#	Article	IF	CITATIONS
19	Paroxysmal itch caused by gain-of-function Nav1.7 mutation. Pain, 2014, 155, 1702-1707.	2.0	78
20	Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial. Lancet Neurology, The, 2021, 20, 182-192.	4.9	74
21	Botulinum Toxin type A reduces capsaicin-evoked pain and neurogenic vasodilatation in human skin. Pain, 2007, 130, 76-83.	2.0	66
22	Clinical use of non-a botulinum toxins: botulinum toxin type B. Neurotoxicity Research, 2006, 9, 121-125.	1.3	62
23	Neurophysiological study of corticomotor pathways in restless legs syndrome. Clinical Neurophysiology, 2003, 114, 1638-1645.	0.7	61
24	Surgery for insular low-grade glioma: predictors of postoperative seizure outcome. Journal of Neurosurgery, 2014, 120, 12-23.	0.9	61
25	Management of Parotid Sialocele With Botulinum Toxin. Laryngoscope, 1999, 109, 1344-1346.	1.1	58
26	Analysis of the ?-sarcoglycan gene in familial and sporadic myoclonus-dystonia: Evidence for genetic heterogeneity. Movement Disorders, 2003, 18, 1047-1051.	2.2	58
27	The relationship between cerebral vascular disease and parkinsonism: The VADO study. Parkinsonism and Related Disorders, 2012, 18, 775-780.	1.1	58
28	Deep brain stimulation: Subthalamic nucleus electrophysiological activity in awake and anesthetized patients. Clinical Neurophysiology, 2012, 123, 2406-2413.	0.7	58
29	The Surgical Approach to the Anterior Nucleus of Thalamus in Patients With Refractory Epilepsy: Experience from the International Multicenter Registry (MORE). Neurosurgery, 2019, 84, 141-150.	0.6	57
30	Polyneuropathy associated with duodenal infusion of levodopa in Parkinson's disease: features, pathogenesis and management. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 490-495.	0.9	55
31	Pallidal stimulation for segmental dystonia: Long term follow up of 11 consecutive patients. Movement Disorders, 2009, 24, 1829-1835.	2.2	52
32	A New Rechargeable Device for Deep Brain Stimulation: A Prospective Patient Satisfaction Survey. European Neurology, 2013, 69, 193-199.	0.6	50
33	Skin Biopsy May Help to Distinguish Multiple System Atrophy–Parkinsonism from Parkinson's Disease With Orthostatic Hypotension. Movement Disorders, 2020, 35, 1649-1657.	2.2	50
34	The role of gustatory flushing in Frey's syndrome and its treatment with botulinum toxin type A. Clinical Autonomic Research, 2002, 12, 174-178.	1.4	49
35	Clinical use of non-a botulinum toxins: Botulinum toxin type C and botulinum toxin type F. Neurotoxicity Research, 2006, 9, 127-131.	1.3	49
36	Clinical outcome of deep brain stimulation for dystonia: constantâ€current or constantâ€voltage stimulation? A nonâ€randomized study. European Journal of Neurology, 2015, 22, 919-926.	1.7	45

3

#	Article	IF	Citations
37	Clinical Correlates of Functional Motor Disorders: An Italian Multicenter Study. Movement Disorders Clinical Practice, 2020, 7, 920-929.	0.8	45
38	Functional motor disorders associated with other neurological diseases: Beyond the boundaries of "organic―neurology. European Journal of Neurology, 2021, 28, 1752-1758.	1.7	45
39	A decision tool to support appropriate referral for deep brain stimulation in Parkinson's disease. Journal of Neurology, 2009, 256, 83-88.	1.8	44
40	Facial and Bodily Emotion Recognition in Multiple Sclerosis: The Role of Alexithymia and Other Characteristics of the Disease. Journal of the International Neuropsychological Society, 2014, 20, 1004-1014.	1.2	44
41	Body weight and food intake in Parkinson's disease. A review of the association to non-motor symptoms. Appetite, 2015, 84, 204-211.	1.8	44
42	Which patients discontinue? Issues on Levodopa/carbidopa intestinal gel treatment: Italian multicentre survey of 905 patients with long-term follow-up. Parkinsonism and Related Disorders, 2017, 38, 90-92.	1.1	44
43	Effects of an 8-week meditation program on the implicit and explicit attitudes toward religious/spiritual self-representations. Consciousness and Cognition, 2014, 30, 266-280.	0.8	43
44	Environmental risk factors and clinical phenotype in familial and sporadic primary blepharospasm. Neurology, 2011, 77, 631-637.	1.5	42
45	Motor and non-motor outcomes in patients with advanced Parkinson's disease treated with levodopa/carbidopa intestinal gel: final results of the GREENFIELD observational study. Journal of Neurology, 2019, 266, 2164-2176.	1.8	42
46	Switching from constant voltage to constant current in deep brain stimulation: a multicenter experience of mixed implants for movement disorders. European Journal of Neurology, 2016, 23, 190-195.	1.7	41
47	Chronic post-traumatic neuropathic pain of brachial plexus and upper limb: a new technique of peripheral nerve stimulation. Neurosurgical Review, 2014, 37, 473-480.	1.2	39
48	Botulinum neurotoxin serotypes A and C do not affect motor units survival in humans: an electrophysiological study by motor units counting. Clinical Neurophysiology, 2002, 113, 1258-1264.	0.7	37
49	Brain Interstitial Nociceptin/Orphanin FQ Levels are Elevated in Parkinson's Disease. Movement Disorders, 2010, 25, 1723-1732.	2.2	37
50	Botulinum neurotoxin serotype D is poorly effective in humans: An in vivo electrophysiological study. Clinical Neurophysiology, 2013, 124, 999-1004.	0.7	37
51	Prevalence of Neuropathic Pain in Patients with Traumatic Brachial Plexus Injury: A Multicenter Prospective Hospital-Based Study. Pain Medicine, 2017, 18, 2428-2432.	0.9	37
52	Botulinum toxin treatment in patients with focal dystonia and hemifacial spasm. A multicenter study of the Italian Movement Disorder Group. Italian Journal of Neurological Sciences, 1993, 14, 361-367.	0.1	36
53	Multiple system atrophy is distinguished from idiopathic Parkinson's disease by the arginine growth hormone stimulation test. Annals of Neurology, 2006, 60, 611-615.	2.8	36
54	The Italian Dystonia Registry: rationale, design and preliminary findings. Neurological Sciences, 2017, 38, 819-825.	0.9	35

#	Article	IF	CITATIONS
55	Erythropoietin in amyotrophic lateral sclerosis: a multicentre, randomised, double blind, placebo controlled, phase III study. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 879-886.	0.9	32
56	Bilateral striatal necrosis, dystonia and multiple mitochondrial DNA deletions: Case study and effect of deep brain stimulation. Movement Disorders, 2008, 23, 114-118.	2.2	30
57	The processing of actions and action-words in amyotrophic lateral sclerosis patients. Cortex, 2015, 64, 136-147.	1.1	30
58	Short and long-term outcomes after combined intravenous thrombolysis and mechanical thrombectomy versus direct mechanical thrombectomy: a prospective single-center study. Journal of Thrombosis and Thrombolysis, 2017, 44, 203-209.	1.0	30
59	Telemedicine for parkinsonism: A two-step model based on the COVID-19 experience in Milan, Italy. Parkinsonism and Related Disorders, 2020, 75, 130-132.	1.1	30
60	Side and time variability of intraepidermal nerve fiber density. Neurology, 2015, 84, 2368-2371.	1.5	29
61	Weight gain after STN-DBS: The role of reward sensitivity and impulsivity. Cortex, 2017, 92, 150-161.	1.1	28
62	Discrimination of MSA-P and MSA-C by RT-QuIC analysis of olfactory mucosa: the first assessment of assay reproducibility between two specialized laboratories. Molecular Neurodegeneration, 2021, 16, 82.	4.4	28
63	Italian multicentre study of carpal tunnel syndrome: study design. Italian Journal of Neurological Sciences, 1998, 19, 285-289.	0.1	27
64	<i>COL6A5</i> variants in familial neuropathic chronic itch. Brain, 2017, 140, aww343.	3.7	25
65	Functional motor phenotypes: to lump or to split?. Journal of Neurology, 2021, 268, 4737-4743.	1.8	25
66	Clinical duration of action of different botulinum toxin types in humans. Toxicon, 2020, 179, 84-91.	0.8	24
67	A New Implantable Closed-Loop Clinical Neural Interface: First Application in Parkinson's Disease. Frontiers in Neuroscience, 2021, 15, 763235.	1.4	24
68	The effects of healthy aging on mental imagery as revealed by egocentric and allocentric mental spatial transformations. Acta Psychologica, 2013, 143, 146-156.	0.7	23
69	Referring Parkinson's disease patients for deep brain stimulation: a RAND/UCLA appropriateness study. Journal of Neurology, 2016, 263, 112-119.	1.8	23
70	Spatio-temporal structure of single neuron subthalamic activity identifies DBS target for anesthetized Tourette syndrome patients. Journal of Neural Engineering, 2019, 16, 066011.	1.8	23
71	Validated outcome of treatment changes according to International League Against Epilepsy criteria in adults with drugâ€resistant focal epilepsy. Epilepsia, 2019, 60, 1114-1123.	2.6	23
72	Effect of Mindfulness Meditation on Personality and Psychological Well-being in Patients with Multiple Sclerosis. International Journal of MS Care, 2018, 20, 101-108.	0.4	23

#	Article	IF	CITATIONS
73	Emotion recognition in Parkinson's disease after subthalamic deep brain stimulation: Differential effects of microlesion and STN stimulation. Cortex, 2014, 51, 35-45.	1.1	22
74	Idiopathic delayed-onset edema surrounding deep brain stimulation leads: Insights from a case series and systematic literature review. Parkinsonism and Related Disorders, 2016, 32, 108-115.	1.1	22
75	Comparison of 123I-MIBG scintigraphy and phosphorylated $\hat{l}\pm$ -synuclein skin deposits in synucleinopathies. Parkinsonism and Related Disorders, 2020, 81, 48-53.	1.1	22
76	Demographic and clinical determinants of neck pain in idiopathic cervical dystonia. Journal of Neural Transmission, 2020, 127, 1435-1439.	1.4	22
77	The therapeutic use of botulinum toxin. Expert Opinion on Investigational Drugs, 1997, 6, 1383-1394.	1.9	21
78	Idiopathic <scp>Nonâ€ŧask‧pecific</scp> Upper Limb Dystonia, a Neglected Form of Dystonia. Movement Disorders, 2020, 35, 2038-2045.	2.2	21
79	The excitability of the trigeminal motor system in sleep bruxism: a transcranial magnetic stimulation and brainstem reflex study. Journal of Orofacial Pain, 2006, 20, 145-55.	1.7	21
80	The Incidence of Amyotrophic Lateral Sclerosis in Friuli Venezia Giulia, Italy, from 2002 to 2009: A Retrospective Population-Based Study. Neuroepidemiology, 2013, 41, 54-61.	1.1	20
81	Microsubthalamotomy improves sleep in patients affected by advanced Parkinson's disease. Sleep Medicine, 2014, 15, 637-641.	0.8	18
82	Levodopa/carbidopa intestinal gel therapy for advanced Parkinson Disease: AN early toxic effect for small nerve fibers?. Muscle and Nerve, 2016, 54, 970-972.	1.0	18
83	Chronic pain in Gaucher disease: skeletal or neuropathic origin?. Orphanet Journal of Rare Diseases, 2017, 12, 148.	1.2	18
84	Does acute peripheral trauma contribute to idiopathic adult-onset dystonia?. Parkinsonism and Related Disorders, 2020, 71, 40-43.	1.1	18
85	Neuro-telehealth for fragile patients in a tertiary referral neurological institute during the COVID-19 pandemic in Milan, Lombardy. Neurological Sciences, 2021, 42, 2637-2644.	0.9	18
86	Cognitive and brain reserve for mind-body therapeutic approaches in multiple sclerosis: A review. Restorative Neurology and Neuroscience, 2014, 32, 575-595.	0.4	17
87	Progressive multifocal leukoencephalopathy in a patient with Good's syndrome. International Journal of Infectious Diseases, 2010, 14, e444-e447.	1.5	16
88	The Use of Antidepressant Medication before and after the Diagnosis of Amyotrophic Lateral Sclerosis: A Population-Based Cohort Study. Neuroepidemiology, 2015, 44, 91-98.	1.1	16
89	Twenty years of molecular analyses in amyotrophic lateral sclerosis: genetic landscape of Italian patients. Neurobiology of Aging, 2018, 66, 179.e5-179.e16.	1.5	16
90	Cryoglobulinemic neuropathy related to hepatitis C virus infection. Clinical, laboratory and neurophysiological study. Journal of the Peripheral Nervous System, 1996, 1, 131-8.	1.4	16

#	Article	IF	CITATIONS
91	To move or not to move: Subthalamic deep brain stimulation effects on implicit motor simulation. Brain Research, 2014, 1574, 14-25.	1.1	15
92	Short- and long-term motor outcome ofÂSTN-DBS in Parkinson's Disease: focus on sex differences. Neurological Sciences, 2022, 43, 1769-1781.	0.9	15
93	Effect of slow rTMS of motor cortex on the excitability of the Blink Reflex: A study in healthy humans. Clinical Neurophysiology, 2009, 120, 174-180.	0.7	14
94	Protein misfolding, amyotrophic lateral sclerosis and guanabenz: protocol for a phase II RCT with futility design (ProMISe trial). BMJ Open, 2017, 7, e015434.	0.8	14
95	The epidemiology of Parkinson's disease in the Italian region Friuli Venezia Giulia: a population-based study with administrative data. Neurological Sciences, 2018, 39, 699-704.	0.9	14
96	On the action of botulinum neurotoxins A and E at cholinergic terminals. Journal of Physiology (Paris), 1998, 92, 135-139.	2.1	13
97	Hyperhidrosis and sympathetic skin response in chronic alcoholic patients. Clinical Autonomic Research, 1999, 9, 17-22.	1.4	13
98	Second Surgery in Insular Low-Grade Gliomas. BioMed Research International, 2015, 2015, 1-11.	0.9	13
99	Effect of thymectomy on refractory autoimmune status epilepticus. Journal of Neuroimmunology, 2018, 317, 90-94.	1.1	13
100	Unusual Parsonage–Turner syndrome with relapses and bilateral simultaneous anterior interosseous neuropathy. Neurological Sciences, 2009, 30, 513-516.	0.9	12
101	Efficacy of botulinum toxin type A treatment of functional impairment of degenerative hip joint: Preliminary results. Journal of Rehabilitation Medicine, 2010, 42, 691-693.	0.8	12
102	The arginine growth hormone stimulation test in bradykineticâ€ r igid parkinsonisms. Movement Disorders, 2008, 23, 190-194.	2.2	11
103	Quantitative Diffusion Tensor Imaging Analysis of Low-Grade Gliomas: From Preclinical Application to Patient Care. World Neurosurgery, 2017, 97, 333-343.	0.7	11
104	Spread of dystonia in patients with idiopathic adultâ€onset laryngeal dystonia. European Journal of Neurology, 2018, 25, 1341-1344.	1.7	11
105	Is Deep Brain Stimulation still an option for tremor recurrence after Focused Ultrasound thalamotomy? A case report. Journal of Clinical Neuroscience, 2019, 68, 344-346.	0.8	11
106	Managing Parkinson's disease: moving ON with NOP. British Journal of Pharmacology, 2020, 177, 28-47.	2.7	11
107	Introduction of direct oral anticoagulant within 7Âdays of stroke onset: a nomogram to predict the probability of 3-month modified Rankin Scale score >Â2. Journal of Thrombosis and Thrombolysis, 2018, 46, 292-298.	1.0	10
108	Brain impedance variation of directional leads implanted in subthalamic nuclei of Parkinsonian patients. Clinical Neurophysiology, 2019, 130, 1562-1569.	0.7	10

7

#	Article	IF	CITATIONS
109	Levodopa–carbidopa intrajejunal infusion in Parkinson's disease: untangling the role of age. Journal of Neurology, 2021, 268, 1728-1737.	1.8	9
110	AbobotulinumtoxinA: A New Therapy for Hip Osteoarthritis. A Prospective Randomized Double-Blind Multicenter Study. Toxins, 2018, 10, 448.	1.5	8
111	Food knowledge depends upon the integrity of both sensory and functional properties: a VBM, TBSS and DTI tractography study. Scientific Reports, 2019, 9, 7439.	1.6	8
112	Deep brain stimulation of the subthalamic nucleus and the temporal discounting of primary and secondary rewards. Journal of Neurology, 2019, 266, 1113-1119.	1.8	8
113	Botulinum toxin for the management of spasticity in multiple sclerosis: the Italian botulinum toxin network study. Neurological Sciences, 2020, 41, 2781-2792.	0.9	8
114	Spread of segmental/multifocal idiopathic adult-onset dystonia to a third body site. Parkinsonism and Related Disorders, 2021, 87, 70-74.	1.1	8
115	Should We Consider Deep Brain Stimulation Discontinuation in <scp>Lateâ€Stage</scp> Parkinson's Disease?. Movement Disorders, 2020, 35, 1379-1387.	2.2	8
116	Taking care of patients with brain tumor-related epilepsy: results from an Italian survey. Neurological Sciences, 2015, 36, 125-130.	0.9	7
117	Parkinsonism and Nigrostriatal Damage Secondary to <scp><i>CSF1R</i></scp> â€Related Primary Microgliopathy. Movement Disorders, 2020, 35, 2360-2362.	2.2	6
118	Motor and Sensory Features of Cervical Dystonia Subtypes: Data From the Italian Dystonia Registry. Frontiers in Neurology, 2020, 11, 906.	1.1	6
119	Unusual case of Fahr syndrome with motoneuron disease. Italian Journal of Neurological Sciences, 1991, 12, 597-600.	0.1	5
120	Recovery cycle of the masseter inhibitory reflex after magnetic stimulation in normal subjects. Clinical Neurophysiology, 2003, 114, 1253-1258.	0.7	5
121	The Alpha-Synuclein RT-QuIC Products Generated by the Olfactory Mucosa of Patients with Parkinson's Disease and Multiple System Atrophy Induce Inflammatory Responses in SH-SY5Y Cells. Cells, 2022, 11, 87.	1.8	5
122	Formal Semantics in the Neurology Clinic: Atypical Understanding of Aspectual Coercion in ALS Patients. Frontiers in Psychology, 2016, 7, 1733.	1.1	4
123	Post-anoxic status epilepticus: which variable could modify prognosis? A single-center experience. Minerva Anestesiologica, 2017, 83, 1255-1264.	0.6	4
124	Frameless Deep Brain Stimulation Surgery: A Single-Center Experience and Retrospective Analysis of Placement Accuracy of 220 Electrodes in a Series of 110 Patients. Stereotactic and Functional Neurosurgery, 2019, 97, 337-346.	0.8	4
125	Functional gait disorders: Demographic and clinical correlations. Parkinsonism and Related Disorders, 2021, 91, 32-36.	1.1	4
126	PMCA-Based Detection of Prions in the Olfactory Mucosa of Patients With Sporadic Creutzfeldt–Jakob Disease. Frontiers in Aging Neuroscience, 2022, 14, 848991.	1.7	4

#	Article	IF	CITATIONS
127	Globus pallidus internus activity during simultaneous bilateral microelectrode recordings in status dystonicus. Acta Neurochirurgica, 2021, 163, 211-217.	0.9	3
128	Neuroimaging in idiopathic adult-onset focal dystonia. Neurological Sciences, 2021, 42, 2947-2950.	0.9	3
129	An intra-operative feature-based classification of microelectrode recordings to support the subthalamic nucleus functional identification during deep brain stimulation surgery. Journal of Neural Engineering, 2021, 18, 016003.	1.8	3
130	Deep brain stimulation in the management of multiple sclerosis tremor. Neurological Sciences, 2006, 27, s331-s334.	0.9	2
131	CHA2DS2–VASc score predicts short- and long-term outcomes in patients with acute ischemic stroke treated with intravenous thrombolysis. Journal of Thrombosis and Thrombolysis, 2018, 45, 122-129.	1.0	2
132	Lessons from the present: Intraoperative neurophysiological monitoring organization during the COVID-19 pandemic in Lombardy, northern Italy. Clinical Neurophysiology, 2020, 131, 2056-2058.	0.7	2
133	Globus Pallidus Internus Deep Brain Stimulation Using Frame-Based vs. Frameless Stereotaxy in Dystonia: A Single-Center Experience. Frontiers in Neurology, 2021, 12, 643757.	1.1	2
134	A population-based study of injuries to the brachial plexus and to the peripheral nerves of the shoulder girdle and upper limb in the Italian region Friuli Venezia Giulia. Neurosurgical Review, 2018, 41, 519-523.	1.2	1
135	Characterization of Microelectrode Recordings for the Subthalamic Nucleus identification in Parkinson's disease. , 2020, 2020, 3485-3488.		1
136	A video of best practice recommendations for making botulinum toxin therapy safe during the COVID-19 pandemic. Neurological Sciences, 2021, 42, 3937-3938.	0.9	1
137	Biology and Clinical Pharmacology of Botulinum Neurotoxin Type C and Other Non-A/Non-B Botulinum Neurotoxins. , 2009, , 77-84.		0
138	Action and Language Processing in Patients with Motor Neuron Disease. Procedia, Social and Behavioral Sciences, 2012, 61, 4.	0.5	0
139	Different types of botulinum neurotoxins in mouse and human neuromuscular junction. Toxicon, 2013, 75, 222.	0.8	0
140	Neurophysiologic profile in muscular reinnervation of different botulinum toxins in humans. Toxicon, 2018, 156, S23.	0.8	0
141	Use of Non-A/Non-B Botulinum Toxins. , 0, , 137-138.		0
142	Cerebrospinal fluid neuropathological biomarkers in beta-propeller protein-associated neurodegeneration, with complicated parkinsonian phenotype. Parkinsonism and Related Disorders, 2022, 98, 38-40.	1.1	0